A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries

Trial Profile

A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 May 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2016 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.
    • 26 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
    • 26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top